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Figure 1. Forest plot for pain at the end of the trial.Ă
Table 2
Results for Pain, Stiffness and Function
Study Trials N Patients N Effect Size I2
Pain
All timepoints 5 712 -0.07 (-0.24, 0.10) 16%, low
4 weeks 3 547 0.01 (-0.15, 0.18) 0%, no
12 weeks 4 541 -0.05 (-0.28, 0.17) 30%, low
Stiffness 2 159 0.03 (-0.27, 0.34) 0%, no
Function 2 159 -0.08 (-0.39, 0.23) 0%, no
Note: CI ¼ Conﬁdence Interval; I2 ¼ Heterogeneity Score
Figure 1. [PRG4] in ﬂare-SF after IA HA or corticosteroid injection. [PRG4] SEM in
normal (NL) SF (N¼29) shown by black lines. Samples selected for friction testing (HA
ﬂare only) are circled.
Figure 2. HAMW distribution in N¼4 PRG4-deﬁcient ﬂare-SF samples selected for
friction testing and N¼14 normal (NL) SF (#¼ p<0.05)
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EFFECT OF FLARE REACTION TO INTRA-ARTICULAR INJECTION ON
CARTILAGE LUBRICATING ABILITY OF HUMAN SYNOVIAL FLUID
T.E. Ludwig, J.R. McAllister, V.M. Lun, J.P. Wiley, T.A. Schmidt. Univ. of
Calgary, Calgary, AB, Canada
Purpose: In synovial ﬂuid (SF), proteoglycan 4 (PRG4) and hyaluronan
(HA) act synergistically to contribute to the boundary lubrication of
articular cartilage in a dose-dependent manner. Alterations in PRG4 and
HA levels in SF can lead to compromised boundary lubrication, which
can be restored in vitro by lubricant supplementation. Intra-articular
(IA) injections of HA and corticosteroid are common treatments for
osteoarthritis (OA). In vitro studies have suggested that IA HA alonemay
be insufﬁcient to provide chondroprotection, as evidenced by increased
chondrocyte apoptosis during cartilage-on-cartilage friction testing
relative to native SF. A recent review highlighted the small beneﬁt of IA
HA treatment and increased risk of ﬂare reaction (deﬁned as a hot,
painful, swollen knee after injection). The effects of a reaction to IA
treatment on SF lubricant content and lubricating ability are unknown.
The objectives of this study were to 1) quantify PRG4 and HA content in
OA SF after a ﬂare reaction to IA treatment and 2) assess the cartilage
boundary lubricating ability of ﬂare-SF deﬁcient in PRG4, with and
without supplementation with PRG4HA.
Methods: Knee SF was collected from OA patients’ requiring aspiration
after corticosteroid or HA injection (11 days after injection, N ¼ 14.)
PRG4 and HA concentrations in normal (NL, N ¼ 29) and ﬂare-SF were
measured by sandwich enzyme linked immunosorbent assay. HA
molecular weight (MW) distribution was determined by agarose gel
electrophoresis. Lubricating ability of PRG4-deﬁcient ﬂare-SF, PRG4-
deﬁcient ﬂare-SF supplemented with normal levels of PRG4HA, and
NL SF was tested in a normal human cartilage-on-cartilage friction test.
Static, mstatic,Neq, and kinetic, <mkinetic,Neq>, friction coefﬁcients
were calculated.
Results: Flare-SF PRG4 and HA concentrations ranged from below
normal to super-physiological. Four samples deﬁcient in PRG4 ([PRG4],
below the average NL concentration) were selected for friction testing;
all 4 were reactions to IA HA (Fig. 1). HA concentration in the friction
tested ﬂare-SF did not differ from NL (p¼0.5, not shown), while HAMW
was shifted slightly towards the smaller size range (Fig. 2).
<mkinetic,Neq> in PRG4-deﬁcient ﬂare-SF (Fig. 3) was not altered
compared to NL, and no changes were observed with PRG4 or PRG4+HA
supplementation (p¼0.77-1.0).
Conclusions: These results demonstrate that some ﬂare-SF exhibits
altered lubricant composition after reaction to IA injection, as has beenpreviously observed in ACL injury and chronic OA, but can still retain
normal boundary lubricating ability. A dramatic shift towards lower HA
MW in chronic OA SF deﬁcient in PRG4 has previously been observed; an
HA distribution closer to normal SF, as observed here, could contribute to
the normal lubricating ability observed. Other characteristics of PRG4,
including glycosylation and size distribution, remain to be evaluated and
compared between healthy and diseased SF, and may have effects on SF
lubricating ability. Evaluation of OA SF after IA injection over a longer
time course, along with further analysis of PRG4 characteristics, will
provide further insight into effects of inﬂammation on joint lubrication.
Abstracts / Osteoarthritis and Cartilage 21 (2013) S63–S312S300Figure 3. Kinetic friction coefﬁcient (<mkinetic,Neq>) at Tps¼1.2 s of PRG4 deﬁcient
ﬂare-SF with 450 mg/mL PRG4 and 1.0 mg/mL 1.5 MDa HA supplementation, and NLSF.
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CHANGE IN MRI SYNOVITIS CORRELATES WITH CHANGE IN PAIN
FOLLOWING INTRA-ARTICULAR STEROID INJECTION
T.W. O'Neill y, L.M. Forsythe y, M.J. Parkes y, E. Marjanovic y, A. Gait y, C.E.
Hutchinson z, T.F. Cootes y, D.T. Felson y. y The Univ. of Manchester,
Manchester, United Kingdom; zUniv. of Warwick, Coventry, United
Kingdom
Purpose: Synovitis is a well recognised ﬁnding in knee osteoarthritis. It
can be identiﬁed on Magnetic Resonance Imaging (MRI) as synovial
thickening, although injection of contrast material is required to
distinguish synovial tissue from synovial ﬂuid. The aim of this analysis
was to determinewhether change in synovial tissue volume as assessed
using gadolinium (Gd) enhancedMRI imaging correlates with change in
knee pain following intra-articular steroid therapy.
Methods: Men and women aged 40 years and older who met ACR
criteria for the disease, were recruited for participation in an ongoing
open label clinical trial of intra-articular steroid therapy. Subjects who
took part in the study had signiﬁcant knee pain and grade 2 or higher
knee OA. At baseline visit they completed a questionnaire about their
symptoms including KOOS pain scale (100 ¼ no pain to 0 ¼ extreme
pain) and also a VAS score (0 ¼ no pain] to 10 ¼ extreme pain) for pain
on a nominated activity (VASnA). They subsequently had a Gd enhanced
MRI immediately prior to having an intra-articular steroid injection
with repeat questionnaire and Gd-enhanced MRI scan at follow up visit
to assess synovial response usually within 2 weeks after the injection.
To assess synovial tissue volume, sagittal (post CE T1W Fat Suppressed
images: TR 500ms, TE 17ms; FoV 15.9 x 15.9cm; slice thickness 3mm)
scans were obtained. Manual segmentation of the synovial tissue layer
was performed on the post contrast knee image by a single observer.
Using computer image analysis we excluded cartilage within the
segmented space, by thresholding in the associated sagittal (3DWATSc:
TR 20ms, TE 7.7ms, FoV 15cm, 288x288) scan. The rest of the segmented
space was assumed to be a mixture of ﬂuid and synovial tissue. We
calculated the proportion of synovial tissue in every voxel using P ¼ (I -
mf) / (ms - mf) truncated to [0,1], where I is the voxel intensity and mf,
ms are the means of the intensity distributions of ﬂuid and synovial
tissue volume respectively. We looked at mean synovial volume before
and after the steroid injection and looked at the Spearman Rank
correlation coefﬁcient between change in synovial volume and change
in the level of KOOS-pain and also VASnA.
Results: We analysed data from 41 patients. Their mean age was 62.4
years (SD 10.5 years), and 21 were female (51.2%). The median time
between baseline and follow up scan was 9 days (IQR 7 to 14 days). The
median synovial tissue volume at baseline was 7,556mm3 (IQR4,670mm3 to 11,269 mm3), and at follow up was 7,078mm3 (IQR
3,642mm3 to 8,541mm3); median difference -1,007mm3 (95% CI
-1,909mm3 to -320mm3). Both KOOS pain (24.7pts; 95% CI 18.4 pts to
31.0 pts) and VASnA (-3.2cm; 95% CI -4.1cm to -2.2cm) improved
signiﬁcantly between baseline and follow up. The change in synovial
tissue volume correlated with change in VASnA (rs ¼ 0.39; p ¼ 0.01)
though not with KOOS-pain (rs ¼ -0.11 ; p ¼ 0.50). Change in VASnA did
not appear to correlate with synovial tissue volume at baseline (rs ¼
-0.03; p¼0.85); nor did change in KOOS pain (rs ¼ 0.17; p¼0.30).
Conclusions: Synovial tissue volume in knee osteoarthritis, assessed
with Gd-enhanced MRI correlates with change in pain assessed as pain
on a nominated activity, though not KOOS, in response to intra-articular
steroid injection.586
A SYSTEMATIC REVIEW OF WHERE AND HOW TO INJECT IN THE
KNEE?
N. Maricar, M.J. Parkes, M.J. Callaghan, D.T. Felson, T.W. O'Neill. The
Univ. of Manchester, Manchester, United Kingdom
Purpose: The knee can be injected at different anatomic sites with or
without image-guidance. We undertook a systematic review to deter-
mine i) the accuracy of intra-articular knee injection (IAKI) andwhether
this varied by site, use of image-guidance and clinician experience, and
ii) whether accuracy of IAKI was linked with improved therapeutic
response.
Methods:Medline, Embase, AMED, CINAHL, Web of Knowledge and the
Cochrane Central Registers for Controlled Trials up to July 2012 were
searched including additional hand searches of relevant articles. Studies
included were those that evaluated accuracy of steroid injection at one
or more IAKI sites performed either blinded or using image-guidance.
We pooled data across studies to determine accuracy and also differ-
ences in accuracy by injection site when injections were delivered blind
or guided by imaging. Using data from the small number of studies
which permitted within-study comparisons, we performed meta-
analyses (ﬁxed effect model with forest plot) to determine differences
in accuracy of blind and guided injections.
Results: Data from 26 publications were included in the review. Only 5
studies were available for within-study comparison for 4 out of the 8
injection sites. The within-study analyses found guided IAKIs at
superomedial patellar (SMP), medial midpatellar (MMP), superolateral
patellar (SLP) and lateral suprapatellar bursa (LSB) had greater accuracy
using image-guidance than given blind [pooled risk difference 0.09-
0.19]. Using between-study analyses, for blinded IAKIs, the SLP site was
the most accurate [87%] though SMP and lateral sites such as lateral
mid-patellar (LMP) and LSB were also accurate [pooled accuracies 82-
84%]. Overall about one in ﬁve blinded IAKIs were inaccurate. Using data
pooled across studies the MMP [Absolute Risk Difference (ARD) 0.22,
95% Conﬁdence Interval (CI) 0.10-0.33] and the anterolateral joint line
injection approaches [ARD 0.28, 95% CI 0.20-0.35] were least accurate
when performed blinded compared to when performed guided. Overall
there was no signiﬁcant difference in accuracy between the lateral
injection sites and the medial sites [Blinded: ARD 0.04, 95% CI 0.00 to
0.08; Guided: ARD 0.01, 95%CI -0.01 to 0.03]. Adverse events associated
with IAKI at different sites were uncommon, though compared to the
lateral approach, the medial approach was associated with a higher
frequency of adverse events. There was some evidence that experience
of the injector was linked with improved accuracy for blinded though
not image-guided injections. There was no association between accu-
racy of IAKIs and treatment outcome though therewas a paucity of data.
Conclusions: IAKIs are safe and can be accurate when performed blind
depending on injection site. The use of image guidance improves
accuracy of IAKI at all sites. Further studies are required to address the
question whether accurate localisation is linked with a better outcome.587
COMPARATIVE EFFECTIVENESS OF TWO HYALURONIC ACID
FORMULATIONS ON PERCEIVED FUNCTIONAL PERFORMANCE
J. Zeni, Jr. y, L. Snyder-Mackler y, M. Axe y,z. yUniv. of Delaware, Newark,
DE, USA; z First State Orthopaedics, Newark, DE, USA
Purpose: Intra-articular hyaluronic acid (HA) injections are a non-
surgical treatment for knee osteoarthritis (OA) that have the potential to
reduce pain and improve functional ability. Despite potential beneﬁts,
